---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-031470"
form_type: "8-K/A"
ticker: "FENC"
cik: "0001211583"
company_name: "FENNEC PHARMACEUTICALS INC."
filed_at: "2024-03-06T23:59:59+00:00"
generated_at: "2026-06-05T02:22:53.996897+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Fennec pre-announces Q4 2023 net revenue ~$9.2-9.7M, up 41-49% QoQ

## Summary
- Q4 2023 net revenue expected $9.2-9.7M, a 41-49% increase vs Q3 2023.
- Full-year 2023 net revenue expected ~$20.7-21.2M.
- Audited full-year results expected on or about March 26, 2024.

## SEC filing metadata
- accession: 0001104659-24-031470
- form_type: 8-K/A
- ticker: FENC
- cik: 0001211583
- company_name: FENNEC PHARMACEUTICALS INC.
- filed_at: 2024-03-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1211583/000110465924031470/0001104659-24-031470-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1211583/000110465924031470/tm248156d1_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-031470
- JSON: https://secwatch.observer/filing/0001104659-24-031470.json
- Plain text: https://secwatch.observer/filing/0001104659-24-031470.txt

## Key facts
- Earnings Releases
  FENNEC PHARMACEUTICALS INC. reported Fourth quarter 2023 results: revenue approximately $9.2 to $9.7 million.
  - Period: Fourth quarter 2023
  - Revenue: approximately $9.2 to $9.7 million
  - Result: preliminary results
  source text: • Fourth quarter 2023 net revenues are expected to be approximately $9.2 to $9.7 million, which represents approximately a 41-49% increase over the third quarter of 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1211583/000110465924031470/0001104659-24-031470-index.htm
- Earnings Releases
  FENNEC PHARMACEUTICALS INC. reported Full-year 2023 results: revenue approximately $20.7 to $21.2 million.
  - Period: Full-year 2023
  - Revenue: approximately $20.7 to $21.2 million
  - Result: preliminary results
  source text: • Full-year 2023 net revenues are expected to be approximately $20.7 to $21.2 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1211583/000110465924031470/0001104659-24-031470-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.